Equities
Health CareMedical Equipment and Services
  • Price (DKK)114.20
  • Today's Change0.25 / 0.22%
  • Shares traded572.64k
  • 1 Year change+26.44%
  • Beta1.0931
Data delayed at least 15 minutes, as of Nov 25 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ambu A/S is a Denmark-based company engaged in the development, manufacture and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products such as resuscitators, face masks and laryngeal masks. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The Company markets its products worldwide. The Company operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.

  • Revenue in DKK (TTM)5.39bn
  • Net income in DKK235.00m
  • Incorporated1956
  • Employees5.20k
  • Location
    Ambu A/SBaltorpbakken 13BALLERUP 2750DenmarkDNK
  • Phone+45 72252000
  • Fax+45 72252050
  • Websitehttps://www.ambu.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revenio Group Oyj761.18m141.75m5.37bn230.0037.487.1029.707.060.72040.72043.863.810.78344.938.17472,574.1014.6714.3317.0917.9049.2950.7318.7221.131.5134.570.127655.81-0.412525.80-12.1518.7217.676.30
Arjo AB (publ)7.25bn331.38m5.47bn6.85k17.691.155.630.75411.881.8841.0528.870.71494.546.781,644,896.003.263.554.625.5543.6444.014.565.410.6263.970.407343.0110.035.976.9010.15-8.8910.35
Biotage AB1.38bn166.66m8.05bn675.0048.293.2628.335.833.213.2126.5647.600.43121.597.223,155,786.005.2110.746.0512.7762.6761.4012.0815.751.1543.880.061640.1119.5415.50-8.217.9714.051.30
ChemoMetec A/S407.87m136.28m8.22bn173.0060.3214.5453.3820.167.837.8323.4432.480.61120.7456.972,357,630.0020.4227.9624.4035.1078.8079.5733.4135.023.76--0.0073144.08-8.2218.37-23.7226.649.97-11.81
Xvivo Perfusion AB486.76m132.47m9.22bn161.0068.636.8351.5318.956.586.5824.0766.130.33251.144.674,691,194.009.051.249.681.3374.4173.1427.214.764.23--0.01170.0043.8826.04398.2948.5721.35--
AddLife AB6.49bn75.87m10.09bn2.36k137.493.1414.831.550.96010.960182.1642.090.76253.505.584,351,152.000.90635.311.298.8337.3036.891.195.790.6381.660.514631.736.6231.30-60.428.0044.43-1.89
Elekta AB (publ)11.75bn734.75m15.08bn4.57k21.302.2510.071.282.962.9647.3828.010.58223.162.893,903,469.003.654.196.537.5136.7639.036.277.370.74253.910.419668.607.415.9838.071.6820.065.92
Embla Medical hf6.01bn494.30m15.43bn4.00k31.422.7517.452.571.151.1513.9513.130.57552.236.651,503,869.004.754.065.514.7662.0262.478.256.911.266.590.40743.999.335.0937.34-6.056.50--
Vitrolife AB2.30bn-2.47bn19.45bn1.10k--2.28--8.44-28.10-28.1026.2497.030.18673.486.483,293,791.00-19.99-4.57-20.71-4.7858.1658.38-107.03-21.892.369.240.135--8.6024.99-1,077.41---7.953.30
Ambu A/S5.39bn235.00m26.78bn5.20k128.915.4328.764.970.88390.883920.2621.000.76942.217.141,037,529.003.353.223.913.8759.3859.544.364.431.4758.640.090725.4112.9013.8439.88-5.812.060.00
Getinge AB21.78bn1.10bn27.69bn11.85k27.061.5111.611.276.216.21123.33111.090.59372.517.302,861,487.003.015.314.006.9845.8047.835.078.690.596510.340.262937.8712.495.66-3.17---0.394434.49
Sectra AB1.17bn290.03m32.23bn1.22k118.7432.0990.8727.462.312.319.368.550.6136--3.631,503,436.0015.1615.7528.0829.5247.0164.9524.7119.59----0.0270.0026.844.0614.2516.5848.37--
Demant A/S22.38bn2.65bn58.85bn21.50k22.216.14--2.6311.9810.92101.2343.360.71922.035.681,034,778.008.528.2711.6813.2375.4574.1411.8511.341.065.580.62440.0013.8910.0012.236.968.80--
Data as of Nov 25 2024. Currency figures normalised to Ambu A/S's reporting currency: Danish Krone DKK

Institutional shareholders

28.51%Per cent of shares held by top holders
HolderShares% Held
Schroder Investment Management Ltd.as of 31 Aug 202417.52m7.46%
Allianz Global Investors GmbHas of 31 Jul 20247.59m3.23%
Capital Research & Management Co. (World Investors)as of 30 Sep 20246.92m2.94%
The Vanguard Group, Inc.as of 06 Nov 20246.54m2.79%
Fundsmith LLPas of 30 Jun 20245.31m2.26%
Brown Capital Management LLCas of 30 Jun 20245.29m2.25%
Artisan Partners LPas of 30 Sep 20245.24m2.23%
Capital International Ltd.as of 30 Sep 20244.67m1.99%
Norges Bank Investment Managementas of 30 Jun 20244.48m1.91%
Baillie Gifford & Co.as of 31 Oct 20243.42m1.46%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.